FIELD: medicine; pharmaceutics.
SUBSTANCE: invention relates to compounds of formulas IA, IB, IC, ID or to their pharmaceutically acceptable salts. Invention also relates to a pharmaceutical composition, a pharmaceutical combination, and a method of treating or preventing a disease or pathological condition for which a JAK1 inhibitor is indicated, based on said compounds.
EFFECT: obtaining novel compounds which can be used in medicine as medicinal agents for treating diseases for which a JAK1 inhibitor is indicated.
17 cl, 2 dwg, 5 tbl, 4 ex
Title | Year | Author | Number |
---|---|---|---|
TREATMENT OF HYDRADENITIS WITH JAK INHIBITORS | 2020 |
|
RU2805595C1 |
CRYSTALLINE PYRIMIDINYL-3,8-DIAZABICYCLO[3.2.1]OCTANYLMETHANONE AND ITS APPLICATIONS | 2020 |
|
RU2803145C2 |
CONDENSED DERIVATIVES OF IMIDAZOLE AND PYRAZOLE AS MODULATORS OF ACTIVITY TNF | 2014 |
|
RU2686117C1 |
COMPOUNDS TARGETING BRM AND RELATED USES THEREOF | 2019 |
|
RU2797832C2 |
CYCLOALKYL NITRILE PYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | 2014 |
|
RU2655380C2 |
PHARMACEUTICAL COMPOUNDS | 2019 |
|
RU2821941C2 |
OXADIAZOLES AS MUSCARINIC RECEPTOR AGONISTS M AND/OR M | 2019 |
|
RU2817018C2 |
PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES | 2021 |
|
RU2819004C1 |
BICYCLIC KETONES AND METHODS OF THEIR USE | 2018 |
|
RU2797922C2 |
C-ARYL GLUCOSIDE DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF | 2011 |
|
RU2606501C2 |
Authors
Dates
2024-04-15—Published
2021-06-30—Filed